A team of Chinese researchers says it can put a genetically engineered probiotic on US pharmacy shelves within two years, a product designed to sense blood sugar and release a therapeutic compound in real time. The so called smart probiotic is being developed as a living medicine for diabetes, and its creators believe it could offer an alternative to daily injections.
The project is led by a group at a Chinese university, with clinical trials expected to begin soon. The team has already tested the engineered bacteria in animals, where it successfully lowered blood glucose levels. Now they are pushing to move from lab to market at a speed that is unusual for biologic drugs.
A bacteria that acts like a tiny pharmacy
The probiotic is a strain of Lactobacillus, a common microbe found in fermented foods and the human gut. Researchers have modified it to carry a genetic circuit that detects glucose and responds by producing a peptide that mimics a natural hormone. When blood sugar rises, the bacteria switch on and release the compound. When levels drop, they quiet down.
This on demand response is what makes the treatment "smart". Instead of a patient measuring glucose and then deciding how much insulin to take, the probiotic would do the sensing and dosing on its own. The team says this could reduce the risk of hypoglycemia, a dangerous side effect of conventional insulin therapy.
From Shanghai lab to American drugstores
The researchers are working with a US partner to navigate the Food and Drug Administration's approval process. They plan to file an investigational new drug application within months, and if trials go well, they hope to launch the product in the United States by 2027. The choice of the US market is strategic: it has a clear regulatory path for live biotherapeutic products, and a large population of diabetes patients who might benefit.
In China, where the team is based, diabetes affects more than 100 million people. Local patients have shown strong interest in the idea of a probiotic that could replace needles, and the team has received inquiries from hospitals and patients asking when it will be available. The researchers say they are also considering a parallel approval track in China, but the US timeline is their priority.
The science is still early, and the team acknowledges that human trials will be the real test. But the prospect of a living medicine that patients could swallow like a yogurt drink has captured attention in both countries. If it works, it would mark a shift in how chronic diseases are managed, moving from synthetic drugs to engineered organisms that work inside the body.
For now, the probiotic remains a promising experiment. Its creators are betting that the same bacteria that help digest food can one day help control a disease that affects hundreds of millions worldwide.
